welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
Pulmonary and Upper Limb Functions in Duchenne Muscular Dystrophy
study id #: NCT03552874
condition: Duchenne Muscular Dystrophy, Upper Limb Function, Respiratory Function Test
Although it is known that the functions of pulmonary and upper limb is affected in late stage of Duchenne Muscular Dystrophy (DMD) negatively, the investigators do not have clear information about its early stage. The aim of this study was to investigate the differences in pulmonary and upper limb functions between children with DMD in early stage and healthy peers.
intervention: The Performance of Upper Limb Questionnaire (PUL)
mechanism of action: No pharmaceutical intervention
last updated: January 08, 2019
start date: January 1, 2017
estimated completion: March 31, 2018
size / enrollment: 47
- Pulmonary Function Test (PFT) [ Time Frame: 5 minutes ]
The pulmonary function tests of the participants were evaluated with a spirometry. The child was asked to perform the spirometric tests for three times with maximum effort. The child was motivated before each attempt for stronger and longer expiration.The result of Pulmonary function Test were recorded.
- The Performance Upper Limb (PUL) [ Time Frame: 15 minutes ]
Upper limb functions of participants were evaluated with The Performance of Upper Limb (PUL) scale. This scale, which was shown to be reliable in DMD, has 22 items in total. It consists of 3 different levels of function: high, mid, and distal. PUL also has four items determining timed performance.
Children with DMD were;
• age between 5-10 years
• being on treatment with corticosteroids for more than 6 months
• being at Level I according to Brooke Upper and Lower Extremity Classification Systems
• age between 5-10 years
• not having any diagnosed disease
Children has undergo surgery and disease affect upper extremity or pulmonary function in last six months.
Unraveling upper extremity performance in DMD: a biophysical modelUpper extremity (UE) activity scales are...
FibroGen Receives Fast Track Designation From the U.S. FDA for Pamrevlumab for the Treatment of Idiopathic Pulmonary...FibroGen, Inc., a biopharmaceutical comp...
Longitudinal Pulmonary Function Testing Outcome Measures in Duchenne Muscular Dystrophy: Long-term Natural History w...We describe changes in pulmonary functio...
Duchenne Pulmonary Awareness: Coughhttps://www.youtube.com/watch?v=V-Qwt3Xz...
Eteplirsen Treatment Attenuates Respiratory Decline in Ambulatory and Non-Ambulatory Patients with Duchenne Muscular...Background: Duchenne muscular dystrophy...
Variables associated with upper extremity function in patients with Duchenne muscular dystrophyPreserving upper extremity (UE) function...
Duchenne Pulmonary Awareness: Nighttime Breathinghttps://www.youtube.com/watch?v=gQLIocbo...